Alphamab Oncology
Alphamab Oncology's GHG Emissions Data Preview
In 2023, Alphamab Oncology completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Alphamab Oncology has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Alphamab Oncology's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Alphamab Oncology amounted to 12,760.81 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Alphamab Oncology increased by 11.32%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Alphamab Oncology's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Alphamab Oncology's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Alphamab Oncology were 3,969.51 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Alphamab Oncology reduced its Scope 1 emissions over time?
Since 2020, Alphamab Oncology's Scope 1 emissions have increased by 76.47%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Alphamab Oncology's Scope 1 emissions increased by 10.1%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Alphamab Oncology's Scope 2 emissions?
In 2023, Alphamab Oncology reported Scope 2 greenhouse gas (GHG) emissions of 8,791.3 tCOâ‚‚e without specifying the calculation method.
Has Alphamab Oncology reduced its Scope 2 emissions over time?
Since 2020, Alphamab Oncology's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 45.26%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Alphamab Oncology's Scope 2 emissions (Unspecified Calculation Method) rose by 11.89% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
What methodology does Alphamab Oncology use for Scope 2 reporting?
In 2023, Alphamab Oncology reported its Scope 2 emissions using an unspecified methodology.
Alphamab Oncology's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Alphamab Oncology's Total Carbon Footprint
In 2023, Alphamab Oncology reported a total carbon footprint of 12,760.81 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 11.32% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Alphamab Oncology's total carbon footprint was Scope 2 emissions, accounting for 68.89% of the company's total carbon footprint, followed by Scope 1 emissions at 31.11%.